Mesoblast drug destined for market
Inflammatory drug developer Mesoblast has received good news which clears the way for its remestemcel-L (Ryoncil) drug to go to market. A panel of the US Oncologic Drugs Advisory Committee (ODAC) of the FDA voted in favour of the view that the “available data support the efficacy” of Ryoncil in cases of transplant rejection. The…